# Nivolumab in non-small cell lung cancer: French evaluation of use, current practices and medicoeconomic approach, Annals of Oncology, Volume 29, viii534, 2018

Françoise Grude, R. Corre, Thierry Urban, J. Bennouna, G. De Chabot, T.

Chatellier, F. Denis, R. Descourt, J-Y. Douillard, C. Ricordel, et al.

► To cite this version:

Françoise Grude, R. Corre, Thierry Urban, J. Bennouna, G. De Chabot, et al.. Nivolumab in non-small cell lung cancer: French evaluation of use, current practices and medicoeconomic approach, Annals of Oncology, Volume 29, viii534, 2018. 43 rd ESMO Congress (ESMO 2018), European Society for Medical Oncology, Oct 2018, Munich, Germany. pp.Page viii534. hal-04437355

HAL Id: hal-04437355

https://hal.science/hal-04437355v1

Submitted on 28 Feb 2024

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

Public Domain
# Nivolumab in non-small cell lung cancer: French evaluation of use, current practices and medico-economic approach, Annals of Oncology, Volume 29, viii534, 2018

F. Grude, Cancer Observatory, ICO Paul Papin, Angers, France

R. Corre, Pneumology, CHU de Pontchaillou, Rennes, France

T. Urban, Pneumology, CHU Angers, Angers, France

J. Bennouna, Pneumology, CHU de Nantes - Laennec, Saint Herblain, France

G. De Chabot, Pneumology, CHU Angers, Angers, France

T. Chatellier, Oncology, Clinique Mutualiste de l'Estuaire, Saint Nazaire, France

F. Denis, Oncology, Clinique Victor Hugo Le Mans, Le Mans, France

R. Descourt, Oncology, C.H.U. Brest - Hôpital Morvan, Brest, France

J-Y. Douillard, Division of Medical and Scientific Affairs, ESMO - European Society for Medical Oncology, Lugano - Viganello, Switzerland,

C. Ricordel, Pneumology, CHU de Pontchaillou, Rennes, France

O. Molinier, Pneumology, Centre Hospitalier Du Mans, Le Mans, France

F. Pinchie, Pneumology, CHU Angers, Angers, France

G. Robinet, Oncology, C.H.U. Brest - Hôpital Morvan, Brest, France

M. Travers, University of Nantes, Nantes, France

B. Moiteaux, University of Nantes, Nantes, France

D. Deniel Lagadec, Cancer Observatory, CHRU Brest, Brest, France

F. Marhuenda, Cancer Observatory, ICO Paul Papin, Angers, France

**Background:** In 2016, nivolumab could be prescribed according to French registration in stage IIIB/IV NSCLC after disease progression with prior platinum-based chemotherapy and TKI therapy for patients with EGFR mutation. The Observatory of Drugs, Medical Devices and Therapeutic Innovations (OMEDIT), a network from the Health Ministry has evaluated the use, current practices and medico-economic approach in the Bretagne and Pays de la Loire areas.

**Methods:** All consenting adult patients with stage IIIB/IV NSCLC who initiated nivolumab (3 mg/kg every 2 weeks) in 2016 were included. Minimum follow-up for survival was 12 months. Sex, age, mutation profile, toxicities, Clinic Benefit (CB: pts with complete/partial response/stable disease as the best response), progression-free survival (PFS) and overall survival (OS) have been studied for ECOG PS 0-1 pts (according to registration).

**Results:** 377 pts with squamous (113 pts), non-squamous (197) and undifferentiated (67) NSCLC have been included. The median number of courses was 8 (1-54). 140 pts (37%) had 1 to 4 courses, 67 pts (18%) 5 to 8 courses and 170 pts (45%) more than 8. 247 pts were treated in 2nd line, 98 in 3rd line. All lines combined, CB was experienced by 212 pts (56%). For these pts, median course was 17 (1-54), mPFS and mOS were 4.6 months and 15.0 months, respectively. No difference on survival has been noticed according to histology, treatment line, age (cut-off 70 y), grade III/IV toxicity. However, mPFS and mOS were lower in ECOG PS 2 pts than in PS0-1 pts: 2.4 months vs 4.6 m (p < 0.01) for PFS and 3.7 m vs 15.0 m (p < 0.001) for OS. 20% of pts presented grade III/IV toxicities. These pts presented a better CB (74% vs 56%, p ¼ 0.002). In 2016-2017, this treatment, for pts initiated in 2016 only, cost 15.8 million.